Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company will engage in a fireside chat and investor meetings on Tuesday, December 3, 2024, at 7:30 a.m. Eastern time.
The event will be accessible via webcast through the 'Events & Presentations' section of Spyre's investor relations website at ir.spyre.com, with a replay available after the conference.
Spyre Therapeutics (NASDAQ: SYRE), un'azienda biotech in fase clinica focalizzata sul trattamento della Malattia Infiammatoria Intestinale (IBD), ha annunciato la sua partecipazione alla 7a Conferenza Annuale Evercore ISI HealthCONx. L'azienda parteciperà a un colloquio informale e a incontri con gli investitori martedì 3 dicembre 2024, alle 7:30 ora orientale.
L'evento sarà disponibile in streaming attraverso la sezione 'Eventi e Presentazioni' del sito web delle relazioni con gli investitori di Spyre all'indirizzo ir.spyre.com, con una registrazione disponibile dopo la conferenza.
Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en etapa clínica centrada en el tratamiento de la Enfermedad Inflamatoria Intestinal (IBD), ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. La empresa participará en una charla informal y en reuniones con inversores el martes 3 de diciembre de 2024, a las 7:30 a.m. hora del Este.
El evento estará disponible a través de una transmisión en línea en la sección 'Eventos y Presentaciones' del sitio web de relaciones con inversores de Spyre en ir.spyre.com, con una grabación disponible después de la conferencia.
Spyre Therapeutics (NASDAQ: SYRE)는 염증성 장질환 (IBD) 치료에 중점을 둔 임상 단계의 생명공학 회사로, 제7회 연례 Evercore ISI HealthCONx 컨퍼런스에 참석할 예정이라고 발표했습니다. 이 회사는 2024년 12월 3일 화요일 오전 7시 30분 동부 표준시에 화로 옆 대화와 투자자 회의에 참여할 것입니다.
이벤트는 Spyre의 투자자 관계 웹사이트 ir.spyre.com의 '이벤트 및 발표' 섹션을 통해 웹캐스트로 시청할 수 있으며, 컨퍼런스 이후 재방송도 제공됩니다.
Spyre Therapeutics (NASDAQ: SYRE), une entreprise biopharmaceutique en phase clinique axée sur le traitement de la Maladie Inflammatoire Intestinale (IBD), a annoncé sa participation à la 7e Conférence Annuelle Evercore ISI HealthCONx. L'entreprise participera à une discussion informelle et à des réunions avec des investisseurs le mardi 3 décembre 2024, à 7h30, heure de l'Est.
L'événement sera accessible en webcast dans la section 'Événements et Présentations' du site web des relations investisseurs de Spyre à l'adresse ir.spyre.com, avec une rediffusion disponible après la conférence.
Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Entzündlichen Darmkrankheiten (IBD) konzentriert, hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz angekündigt. Das Unternehmen wird am Dienstag, den 3. Dezember 2024, um 7:30 Uhr Eastern Time an einem informellen Gespräch und Investorenmeetings teilnehmen.
Die Veranstaltung wird über einen Webcast in der Rubrik 'Veranstaltungen & Präsentationen' auf der Investor-Relations-Website von Spyre unter ir.spyre.com verfügbar sein, mit einer Aufzeichnung nach der Konferenz.
- None.
- None.
- Tuesday, December 3, 2024, at 7:30 a.m. Eastern time
To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay following the end of the conference.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-302315865.html
SOURCE Spyre Therapeutics, Inc.
FAQ
When is Spyre Therapeutics (SYRE) presenting at the Evercore ISI HealthCONx Conference 2024?
How can investors watch Spyre Therapeutics' (SYRE) presentation at the HealthCONx Conference?
What is the main therapeutic focus of Spyre Therapeutics (SYRE)?
Will there be a replay available of Spyre Therapeutics' (SYRE) HealthCONx Conference presentation?
